Synthesis of novel indolyl-1,2,4-triazoles as potent and selective anticancer agents

dc.contributor.authorKumar, Dalip
dc.date.accessioned2021-10-27T04:21:02Z
dc.date.available2021-10-27T04:21:02Z
dc.date.issued2010-12
dc.description.abstractA diverse series of 22 indolyl-1,2,4-triazole congeners (6 and 7) have been synthesized from the reaction of indole-3-carbonitrile (4) or (5) with appropriate acid hydrazides in the presence of potassium carbonate. Synthesized compounds were evaluated for their cytotoxicity against six human cancer cell lines, and some of the compounds displayed promising activity. In particular, 3-(3′,4′,5′-trimethoxyphenyl)-5-(N-methyl-3′-indolyl)-1,2,4-triazole (7i) and 3-(4′-piperidinyl)-5-(N-methyl-3′-indolyl)-1,2,4-triazole (7n) were the most promising and broadly active compounds against the tested cell lines. It was interesting to note that the trimethoxyphenyl analog 7i showed twofold selective cytotoxicity against PaCa2 cell line (IC50 0.8 μm), whereas piperidinyl analog 7n was found to be selectively cytotoxic against MCF7 cell line (IC50 1.6 μm). Notably, the 4-fluorophenyl derivative 7c exhibited selective cytotoxicity against PC3 cell line (IC50 4 μm). The structure–activity relationship study revealed that substituents including 3,4,5-trimethoxyphenyl, 3,4-dimethoxyphenyl, 4-benzyloxy-3-methoxyphenyl, 4-piperidinyl, 4-fluorophenyl and N-methylindole are beneficial for the activity of indolyl-1,2,4-triazoles (6 and 7).en_US
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/j.1747-0285.2010.01051.x
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/3055
dc.language.isoenen_US
dc.publisherWileyen_US
dc.subjectChemistryen_US
dc.subjectNovel Indolyl-1,2,4-triazolesen_US
dc.subjectAnticancer agentsen_US
dc.subjectSynthesisen_US
dc.titleSynthesis of novel indolyl-1,2,4-triazoles as potent and selective anticancer agentsen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: